Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CT020
- Development stage
- Preclinical
- Lead developer
- Clover Therapeutics
01
Overview
CT020 is an early-stage therapeutic candidate under development by Clover Therapeutics for the treatment of both dry and wet age-related macular degeneration (AMD). Clover Therapeutics employs a genetics-first approach to drug discovery, utilizing large-scale genomic data and longitudinal clinical information from its observational studies, such as DIVERSITY and PROGRESSION, to identify and validate novel targets for ophthalmic diseases. As of the current pipeline reporting, CT020 is in the preclinical development phase, and its specific biological target, modality, and mechanism of action remain proprietary and undisclosed.
Beyond the preview
Go deeper on CT020.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CT020.